Abstract
The exact effect of opioid analgesics on sleep is to be determined. Although literature data are sporadically reported, the aim of this review is to summarize the already known effects of such medications on sleep.
A variety of effects, both positive and negative, has been suggested, when opioids are used for pain treatment, but in the absence of pain as well. Although often thought to promote restful sleep, the reality is much more complicated. Sleep disturbances and alterations of sleep quantity and quality have been reported. In addition, their sedative effects have been relatively well established and opioids can cause respiration to slow and become irregular, leading to hypercapnia and hypoxia. As a result, their usage has been linked to irregular or ataxic breathing (Biot’s breathing) and their use has been associated with both central and obstructive sleep apnea. One could estimate that central apnea is a common complication of such chronic therapy, affecting between 30% and 90% of patients. Thus, sleep disturbances can be induced or deteriorated. On the other hand, extended release opioid formulations have been suggested to improve sleep due to no analgesic gaps and less walking because of breakthrough pain. Furthermore, several reports have shown significantly improved sleep quantity and adequacy, with reduced sleep disturbances.
Still, as no prospective trials on the effect of opioid therapy on sleep are available and evidence is scarce, definitive conclusions cannot be drawn. Future studies with their effect on sleep as primary end-point are needed to draw permanent conclusions.
Keywords: Opioids, sleep, disturbance, sedation, breathing, central, obstructive apnea.
Current Pharmaceutical Design
Title:Non-Analgesic Effects of Opioids: Opioids’ Effects on Sleep (Including Sleep Apnea)
Volume: 18 Issue: 37
Author(s): Irene Panagiotou and Kyriaki Mystakidou
Affiliation:
Keywords: Opioids, sleep, disturbance, sedation, breathing, central, obstructive apnea.
Abstract: The exact effect of opioid analgesics on sleep is to be determined. Although literature data are sporadically reported, the aim of this review is to summarize the already known effects of such medications on sleep.
A variety of effects, both positive and negative, has been suggested, when opioids are used for pain treatment, but in the absence of pain as well. Although often thought to promote restful sleep, the reality is much more complicated. Sleep disturbances and alterations of sleep quantity and quality have been reported. In addition, their sedative effects have been relatively well established and opioids can cause respiration to slow and become irregular, leading to hypercapnia and hypoxia. As a result, their usage has been linked to irregular or ataxic breathing (Biot’s breathing) and their use has been associated with both central and obstructive sleep apnea. One could estimate that central apnea is a common complication of such chronic therapy, affecting between 30% and 90% of patients. Thus, sleep disturbances can be induced or deteriorated. On the other hand, extended release opioid formulations have been suggested to improve sleep due to no analgesic gaps and less walking because of breakthrough pain. Furthermore, several reports have shown significantly improved sleep quantity and adequacy, with reduced sleep disturbances.
Still, as no prospective trials on the effect of opioid therapy on sleep are available and evidence is scarce, definitive conclusions cannot be drawn. Future studies with their effect on sleep as primary end-point are needed to draw permanent conclusions.
Export Options
About this article
Cite this article as:
Panagiotou Irene and Mystakidou Kyriaki, Non-Analgesic Effects of Opioids: Opioids’ Effects on Sleep (Including Sleep Apnea), Current Pharmaceutical Design 2012; 18 (37) . https://dx.doi.org/10.2174/138161212803582450
DOI https://dx.doi.org/10.2174/138161212803582450 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hydroxamate, a Key Pharmacophore Exhibiting a Wide Range of Biological Activities
Mini-Reviews in Medicinal Chemistry Neuroprotection by Alpha 2-Adrenergic Agonists in Cerebral Ischemia
Current Neuropharmacology Antioxidant, Antimicrobial Activity and Medicinal Properties of Grewia asiatica L.
Medicinal Chemistry Perioperative Management of Obese Parturients
Current Women`s Health Reviews Vaccine Development for Group A Streptococcus Infections and Associated Diseases
Current Drug Targets Traumatic Brain Injury: Preclinical Imaging Diagnostic(s) and Therapeutic Approaches
Current Pharmaceutical Design Extracellular Matrix Remodeling in Hypertension
Current Hypertension Reviews Bioactive Peptides in Preventative Healthcare: An Overview of Bioactivities and Suggested Methods to Assess Potential Applications
Current Pharmaceutical Design Perioperative Considerations in Patients with Obstructive Sleep Apnea
Current Respiratory Medicine Reviews Pulmonary Embolism Response Team (PERT) - A New Paradigm for the Treatment of Pulmonary Embolism
Current Pharmaceutical Design Aliskiren: A Novel Renin Inhibitor for Hypertension
Current Drug Therapy Editorial: Cures of Vascular Disease - The State
Current Vascular Pharmacology Indications for Non-Invasive Ventilation in Respiratory Failure
Reviews on Recent Clinical Trials Comparative Bioavailability of Two Oral Formulations of Clozapine in Steady State Administered in Schizophrenic Volunteers Under Individualized Dose Regime
Current Clinical Pharmacology Management of Cardiogenic Shock due to Thyrotoxicosis: A Systematic Literature Review
Current Cardiology Reviews Echocardiographic Hemodynamic Monitoring in the Critically Ill Patient
Current Cardiology Reviews Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation Renin-Angiotensin-Aldosterone System: A Current Drug Target for the Management of Neuropathic Pain
Current Drug Targets Fibrates in the Chemical Action of Daunorubicin
Current Cancer Drug Targets Nitric Oxide in the Dorsal Medulla Modulates Excitatory Somatosympathetic Reflexes
Current Cardiology Reviews